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Asymptomatic Atrial Fibrillation. Introduction: The long-term efficacy of radiofrequency catheter
ablation of atrial fibrillation (AF) has been based on patient-reported symptoms suggestive of AF. However,
asymptomatic recurrences of AF may remain undetected. The aim of this study was to determine the
prevalence of asymptomatic recurrences of AF after an apparently successful catheter ablation procedure
for AF.
Methods and Results: Among 244 consecutive patients (mean age 53 ± 11 years) who underwent a pul-
monary vein isolation procedure for symptomatic paroxysmal AF and who reported no symptoms of recur-
rent AF at ≥6 months after the procedure, 60 patients with a history of ≥1 episode of AF per week were
asked to participate in this study. Preablation, these patients had experienced 19 ± 13 episodes of AF per
month. The patients were provided with a patient-activated transtelephonic event recorder for 30 days, a
mean of 642 ± 195 days after the ablation procedure, and were asked to record and transmit recordings on
a daily basis and whenever they felt palpitations. Seven patients (12%) felt palpitations during the study,
although they had not experienced symptoms previously. Each of these 7 patients had an episode of AF
documented with the event monitor during symptoms. In these 7 patients, the mean number of episodes per
month decreased from 19 ± 14 preablation to 3 ± 1 postablation (P < 0.001). Among the 53 asymptomatic
patients, an episode of AF was captured in 1 (2%) patient during the study period.
Conclusion: Asymptomatic recurrences of AF after an apparently successful catheter ablation procedure
for symptomatic paroxysmal AF are infrequent. (J Cardiovasc Electrophysiol, Vol. 15, pp. 920-924, August
2004)
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Introduction
With recognition of the critical role of the pulmonary veins
in atrial fibrillation (AF),1,2 a variety of approaches to ra-
diofrequency catheter ablation of AF have been developed.3-8
The clinical efficacy of these ablation procedures has been
based in large part on patient-reported symptoms sugges-
tive of AF, often confirmed with an ECG recording. Because
most patients undergo an ablation procedure for symptomatic
episodes of AF, the absence of symptoms during follow-up
has been used as an indicator of freedom from recurrent AF.
However, it is well known that patients with symptomatic AF
also may have asymptomatic episodes of AF.9,10 Therefore,
reliance on patient-reported symptoms may result in an over-
estimate of the efficacy of catheter ablation procedures for
AF.
The aim of this study was to investigate the prevalence of
asymptomatic episodes of AF in patients who had an appar-
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ently successful outcome after a catheter ablation procedure
for symptomatic paroxysmal AF.
Methods
Study Subjects
Among 244 consecutive patients with symptomatic parox-
ysmal AF who underwent a pulmonary vein isolation proce-
dure, 165 were completely asymptomatic at follow-up ≥6
months. Based on a detailed clinical history obtained dur-
ing a clinical visit prior to the ablation procedure, patients
who used to experience ≥1 episode of paroxysmal AF per
week were identified among these patients. Subsequently, 60
patients from this pool were randomly chosen and asked to
participate in this study. The clinical characteristics of the
study subjects and the patient pool from which they were
selected were similar (Table 1).
Ablation Procedure
Pulmonary vein isolation was performed by segmental os-
tial applications of radiofrequency energy. This technique
has been described in detail previously.3,4,11 Briefly, af-
ter transseptal catheterization, systemic anticoagulation was
achieved with intravenous heparin to maintain an activated
clotting time of 250 to 350 seconds. A deflectable, de-
capolar catheter with a distal ring configuration (LassoTM
catheter, Biosense Webster, Diamond Bar, CA, USA) and
a deflectable, quadripolar 7-French catheter with 2-5-2 mm
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TABLE 1
Clinical Characteristics
All Patients (n = 244) Successful Outcome After Ablation (n = 165) Study Subjects (n = 60)
Age (years) 53 ± 11 52 ± 12 52 ± 9
Gender (M/F) 200/44 130/35 54/6
Duration (years) 8 ± 7 7 ± 7 8 ± 8
Frequency (per month) 15 ± 13 15 ± 14 17 ± 14
LVEF 0.55 ± 0.04 0.55 ± 0.05 0.55 ± 0.02
LA size (mm) 40 ± 5 40 ± 6 39 ± 3
Structural heart disease 25 15 5
Data are given mean ± SD.
There were no significant differences among the groups.
LA = left atrium; LVEF = left ventricular ejection fraction.
interelectrode spacing and a 4-mm distal electrode with
an embedded thermistor (EP Technologies, Inc., Moun-
tain View, CA, USA) were inserted into the left atrium. A
quadripolar electrode catheter was positioned in the coro-
nary sinus. Pulmonary vein isolation was performed by ap-
plications of radiofrequency energy at ostial sites that dis-
played a rapid pulmonary vein tachycardia during AF4,11 or
pulmonary vein potentials with the earliest bipolar activation
and/or most rapid unipolar intrinsic deflection.12,13 Radiofre-
quency energy was applied at a target temperature of 52◦C
and maximum power of 30 to 35 W for 20 to 40 seconds.
Elimination of all pulmonary vein potentials and complete
entrance block into pulmonary veins were the endpoints of
ablation.
After the procedure, all patients were anticoagulated with
intravenous heparin for 12 to 18 hours. The patients then were
discharged and treated with low-molecular-weight heparin
for 4 to 5 days and warfarin for at least 6 weeks. A repeat
ablation procedure was performed in 36 (15%) of the 244
patients.
Because a history of typical atrial flutter or inducibility of
atrial flutter during the ablation procedure may indicate a high
probability of recurrent atrial flutter after pulmonary vein
isolation for AF,14 cavotricuspid isthmus ablation also was
performed in 4 of the 60 patients, as described previously.15
Follow-Up
All patients were seen in an outpatient clinic 1 to 3 months
after the catheter ablation procedure and every 3 to 6 months
thereafter. All patients who reported palpitations or other
symptoms suggestive of an arrhythmia during follow-up were
provided with an event monitor to document the cause of their
symptoms.
Study Protocol
The study protocol was approved by the Institutional Re-
view Board at the University of Michigan. All patients pro-
vided written informed consent.
At a mean of 642 ± 195 days after catheter ablation,
the study subjects were provided with a patient-activated,
transtelephonic continuous loop recorder (Heart Aide Mini,
TZ Medical Inc., Portland, OR, USA) for 30 days and were
asked to provide a 3-minute rhythm recording at least once
a day. The recordings were acquired randomly throughout
the day; there was no predefined hour or portion of the day.
In addition, they were asked to provide recordings if any
palpitations or symptoms suggestive of AF occurred during
the 30 days. The recordings were transmitted by telephone
and recorded digitally at a data center. All rhythm recordings
were reviewed by an electrophysiologist and categorized as
AF, atrial flutter, atrial tachycardia, atrial premature beats,
ventricular premature beats, nonsustained ventricular tachy-
cardia, or sinus rhythm.
Statistical Analysis
Data are expressed as mean ± SD with confidence in-
tervals (CIs). Categorical variables were compared by Chi-
square analysis. The main issue addressed by this study was
the prevalence of asymptomatic episodes of AF after a suc-
cessful ablation procedure in patients with paroxysmal AF.
The number of episodes of AF before and after ablation was




The 60 study subjects provided rhythm recordings for a
mean 25 ± 8 days. AF was recorded on 4 ± 2 days in 8
(13%) of the 60 subjects, and atrial flutter was recorded on
2 days in 1 subject (2%) who had not undergone ablation
of the cavotricuspid isthmus. In the remaining 51 patients,
sinus rhythm was recorded on each transmission throughout
the study.
Prevalence of Asymptomatic Episodes of AF
Among the 60 subjects, 1 (2%) was documented to
have two asymptomatic episodes of AF during the 30-day
monitoring.
Prevalence of Symptomatic Episodes of AF in Previously
Asymptomatic Patients
Among the 60 subjects of this study, 7 (12%) developed
symptoms suggestive of AF after being asymptomatic for
536 ± 79 days after the ablation procedure. Electrograms
recorded simultaneously with the symptoms confirmed that
these episodes were due to recurrent AF. The ventricular rate
was 90 ± 2 beats/min and 130 ± 29 beats/min during asymp-
tomatic and symptomatic episodes of AF, respectively.
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Figure 1. Long-term freedom from symptomatic atrial fibrillation (AF) after pulmonary vein isolation among the 244 patients from whom the study subjects
were chosen.
Frequency of Episodes of AF Before and After Ablation
Prior to the ablation procedure, there were 16 ± 13
(±95% CI: 12–21) AF episodes per month among the
subjects who were free from recurrent AF and 19±14 (±95%
CI: 7–32) AF episodes per month among the subjects who
had recurrences of AF after the ablation procedure (P = 0.6).
Among the patients who had a recurrence, AF was less
frequent after the ablation (3 ± 1; ±95% CI: 2–5) episodes
per month) than before the ablation (19 ± 14 episodes per
month; P < 0.001).
Freedom from Recurrent AF After PV Isolation
Among the 60 subjects of this study who had been free
from recurrent AF at 6 months after the ablation, AF recurred
in 8 (13%), 591 ± 163 days after pulmonary vein isolation.
Among the study pool of 244 patients from whom the study
subjects were chosen, 70% were free from symptomatic AF at
6-month follow-up, whereas only 62% were free from symp-
tomatic AF 30 months after PV isolation (Fig. 1). Among the
clinical variables of age, gender, duration and frequency of
symptomatic episodes of AF, left ventricular ejection frac-
tion, presence of structural heart disease, and left atrial size,
there were no independent predictors of recurrent AF >180
days after the ablation procedure.
Discussion
Main Findings
The main finding of this study is that asymptomatic
episodes of AF are infrequent in patients with symptomatic
paroxysmal AF who undergo pulmonary vein isolation and
no longer have symptomatic AF. Also of note is that several
patients who initially had an excellent response to pulmonary
vein isolation had recurrences of symptomatic AF as late as
2 years after the ablation procedure.
Asymptomatic and Symptomatic AF
All of the patients who underwent pulmonary vein
isolation in this study had symptomatic AF. A prior study
documented that patients with symptomatic paroxysmal AF
often also have asymptomatic episodes.10 There are two pos-
sible explanations for why asymptomatic episodes of AF
were found in only one patient in this study. One possibil-
ity is that the patients selected to undergo catheter ablation
were particularly symptomatic and less likely than most pa-
tients to have asymptomatic episodes of AF. Another possi-
bility is that the patients in this study had both symptomatic
and asymptomatic episodes of AF preablation, and that pul-
monary vein isolation was equally effective in eliminating the
symptomatic and asymptomatic episodes. In theory, the only
possible reason that catheter ablation would eliminate symp-
tomatic AF more effectively than asymptomatic AF would be
a placebo effect of the procedure. Because prolonged mon-
itoring to detect asymptomatic episodes of AF was not per-
formed before catheter ablation, the actual explanation for
why asymptomatic episodes of AF were infrequent after ab-
lation is unknown.
Patients with paroxysmal AF may become symptomatic
because of an abrupt increase in heart rate. If the ventricular
rate is well controlled, there may be little perceivable change
in the ventricular rate and patients may remain asymptomatic.
Because none of the patients in this study were being treated
with antiarrhythmic drugs (including negative dromotropic
agents), the average ventricular rate during recurrent episodes
of AF was rapid. This may explain why 7 of the 8 patients
with recurrent AF in the course of this study were symp-
tomatic during the AF. The average ventricular rate in the
single patient who had asymptomatic AF was only 90/minute,
which perhaps explains why the patient was unaware of the
episode.
Of note is that seven patients who had been asymptomatic
for>6 months developed symptomatic AF once they received
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an event monitor and began participation in this study. This
may have simply been due to coincidence, but also it is pos-
sible that the patients became more aware of mild ongoing
symptoms during participation in the study.
Late Recurrences of AF
First recurrences of AF occurred as late as 2 years after
pulmonary vein isolation. One possible explanation for late
recurrences of AF would be the recovery of conduction over
a previously ablated pulmonary vein fascicle. However, re-
covery of conduction usually occurs early after an ablation
procedure, and it seems unlikely that conduction through an
ablated fascicle would resume 2 years postablation. A possi-
ble explanation for late recurrences of AF is the emergence
of arrhythmogenic foci outside of the pulmonary veins. How-
ever, it is important to note that the mechanism of AF often is
multifactorial,16 and there may have been progressive elec-
troanatomic remodeling in the left atrium itself as a result
of aging or underlying structural disease. Late recurrences
of AF may underscore the importance of left atrial substrate
modification, which may render AF less likely to perpetuate
regardless of the primary mechanism.
Prior Studies
A prior study used loop recorder transmissions every
2 weeks for 6 to 9 months and demonstrated that asymp-
tomatic AF occurred in 13% of patients treated with azimilide
and 18% of patients receiving a placebo.9 Most recurrences
of AF occurred within a few weeks after restoration of sinus
rhythm. In the present study, patients needed to be asymp-
tomatic for at least 6 months after ablation. A recent study
demonstrated that asymptomatic recurrent episodes of AF
were infrequent in patients who were asymptomatic after ab-
lation, whereas patients who had symptomatic recurrences
were more likely to have asymptomatic recurrences.17
Perception of symptoms may differ between patients with
paroxysmal and persistent AF, and patients with persistent
AF may be less likely to identify an episode of recurrent AF
once sinus rhythm has been restored. Consistent with this
possibility, a prior report demonstrated that the prevalence
of asymptomatic episodes of AF among patients with parox-
ysmal AF was 4%,10,18 which is markedly lower than the
reported prevalence in patients converted out of persistent
AF.9
Study Limitations
A limitation of this study is that the event monitors were
patient activated, not automatic. It is possible that some
episodes of asymptomatic AF were undetected, particularly
if they were brief in duration or limited to periods of sleep.
Additional studies using automatic recordings obtained with
implanted or wearable monitors will be necessary to more
accurately define the prevalence of asymptomatic AF after
catheter ablation.
The findings of this study apply only to patients with symp-
tomatic paroxysmal AF who undergo pulmonary vein isola-
tion. Although asymptomatic late recurrences of AF were in-
frequent in these patients, this may not be the case in patients
who are less symptomatic, in patients with persistent AF, or
in patients who undergo other types of ablation procedure for
AF.
Conclusion
When pulmonary vein isolation is performed in patients
with symptomatic paroxysmal AF, the elimination of symp-
toms in the absence of antiarrhythmic drug therapy appears
to provide a fairly accurate indicator of efficacy. Although
asymptomatic episodes may occur late after pulmonary vein
isolation, the majority of AF recurrences are associated with
symptoms. Because the first recurrence of AF may occur >2
years after pulmonary vein isolation, a long period follow-
up is necessary to define the long-term efficacy of ablation
procedures for AF.
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